Literature DB >> 991456

Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis.

J C Gluckman, H Beaufils, F Sanchez.   

Abstract

It has been demonstrated that activated C3 products might bind to lymphocyte C3 receptors and inhibit subsequent complement-dependent lymphocyte rosette formation. Sera from patients with various types of chronic glomerulonephritis (GN) have been tested in a complement-dependent rosette inhibition assay using normal donors' lymphocytes as reacting cells. Control subjects consisted of healthy donors and patients with miscellaneous renal and general diseases. Most sera of membranoproliferative GN and of systemic lupus erythematosus, and two-thirds sera of focal glomerolosclerosis patients, significantly inhibited rosette formation. Only 15-40 percent sera of patients with other types of GN were inhibitory. Serum inhibiting activity usually correlated with low serum C3 level (P less than 0.0005), although inhibition could be observed with normal serum C3. However, no correlation was found between a patient's own complement-dependent lymphocyte rosette count and his serum inhibitory activity. These results extend previous findings and suggest that the complement-dependent rosette inhibition assay can be used routinely to detect serum activated complement components either free or bound to immune complexes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 991456      PMCID: PMC1540851     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Homograft survival and serum-blocking factors.

Authors:  L J Quadracci; G E Pierce; G E Striker; J A Tremann; T L Marchioro
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

2.  Inhibition of complement-dependent lymphocyte rosette formation: a possible test for activated complement products.

Authors:  G Ezer; A R Hayward
Journal:  Eur J Immunol       Date:  1974-02       Impact factor: 5.532

3.  Technical aspects of the rosette tests used to detect human complement receptor (B) and sheep erythrocyte-binding (T) lymphocytes.

Authors:  N F Mendes; M E Tolnai; N P Silveira; R B Gilbertsen; R S Metzgar
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

4.  The C3-activator system: an alternate pathway of complement activation.

Authors:  O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

5.  Spontaneous autorosette-forming cells in man. A marker for a subset population of T lymphocytes?

Authors:  J C Gluckman; P Montambault
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

6.  Autoimmune New Zealand mouse. Alterations in C3 receptors, complement-induced clumps and follicular adherence of immune complexes.

Authors:  A Arnaiz-Villena; P Sheldon
Journal:  Immunology       Date:  1975-12       Impact factor: 7.397

7.  Detection of circulating soluble immune complexes in patients with various renal diseases.

Authors:  W D Stühlinger; P J Verroust; L Morel-Maroger
Journal:  Immunology       Date:  1976-01       Impact factor: 7.397

8.  The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases.

Authors:  M D Smith; T M Barratt; A R Hayward; J F Soothill
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

9.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

10.  Receptor for the fourth component of complement on human B lymphocytes and cultured human lymphoblastoid cells.

Authors:  V A Bokisch; A T Sobel
Journal:  J Exp Med       Date:  1974-11-01       Impact factor: 14.307

View more
  6 in total

1.  Clinical significance of immunopathological findings in patients with post-pericardiotomy syndrome. II. The significance of serum inhibition and rosette inhibitory factors.

Authors:  B Maisch; P Schuff-Werner; P A Berg; K Kochsiek
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

2.  Serum-mediated inhibition of lymphocyte Fc gamma receptors in glomerulonephritis.

Authors:  A Bakkaloglu; G P Sandilands; J D Briggs; J R Anderson
Journal:  Clin Exp Immunol       Date:  1980-12       Impact factor: 4.330

3.  Analysis of circulating IgA and detection of immune complexes in primary IgA nephropathy.

Authors:  P Lesavre; M Digeon; J F Bach
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

Review 4.  Autoantibodies and serum inhibition factors (sif) in patients with myocarditis.

Authors:  B Maisch; P A Berg; K Kochsiek
Journal:  Klin Wochenschr       Date:  1980-03-03

5.  In vivo and in vitro action of chloroquine on surface markers of human peripheral lymphocytes.

Authors:  P S Nagarkatti; M Nagarkatti; V C Jain
Journal:  Clin Exp Immunol       Date:  1980-07       Impact factor: 4.330

6.  Studies on immune adherence (C3b) receptor activity of human erythrocytes: relationship between receptor activity and presence of immune complexes in serum.

Authors:  Y Inada; M Kamiyama; T Kanemitsu; C L Hyman; W S Clark
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.